about
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaEarly phase clinical trials to identify optimal dosing and safetyDesigns of drug-combination phase I trials in oncology: a systematic review of the literatureNovel methodologic approaches to phase I, II, and III trialsStatistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsHigh-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trialAplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsA phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Performance of two-stage continual reassessment method relative to an optimal benchmarkPhase I/II adaptive design for drug combination oncology trialsContinual reassessment method for partial ordering.Continual Reassessment and Related Dose-Finding DesignsDesigns for single- or multiple-agent phase I trials.Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data.Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupA phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyPharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialA method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs.Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma.Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment.Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcomaFlexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations.Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancerToxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaPhase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsSafety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
P2860
Q24599447-000F0A40-F662-4E3F-B93F-1CB9E628E5F1Q26865076-4E8E3F20-8C90-4E1B-84E8-4C157C596C15Q26996348-4054CCAF-3235-4243-BF18-29B164985B22Q27012934-EBC277CA-4954-4136-95BF-DCA8CAD92DFEQ27023178-BCF3092E-CA94-452A-9979-9D9215779C92Q28545827-71D1B147-3E1D-49AF-A9B6-FFBAA6F8A417Q28552571-FC3DD5BE-FA68-4B42-8278-1FF110E4F33FQ30275176-6E7E383D-4206-4A99-A3D2-E35A7944ADBAQ30371414-7F11F964-312E-4810-AA3A-DABB4777CA75Q30407451-61315491-8D9E-4A95-9363-F91F218FBB26Q30409168-2F9E6A41-762F-43B9-A075-A988E474AE4EQ30423577-D667D2E0-C4EF-4B95-ACCC-E872BF92D2BEQ30431500-BDF07243-3E24-4975-861F-DB0C903A8F0AQ30434355-44F8FBCF-5528-49EE-A528-FE890764D3B6Q30665810-7B4B394E-8E7A-4D6C-BDD8-93A00A5293E7Q30794443-879A2C1C-6C5B-4173-BA7B-B804E3B3D5FDQ30868533-7ECFD7EA-1F12-4694-B345-72CAF3874D42Q30916465-1E0DB945-7685-46C0-86C2-302429E6BA9EQ33363235-DB19FB30-BADE-4A7E-BAE8-DF0D605A1959Q33370628-9EFB8898-1240-413B-B421-2853FDE20106Q33402671-A1E4E0FB-1928-4F23-BC17-55FF3DDE7F9FQ33406135-EAEC6FA7-1AD7-4F88-ABE0-0028BF7AD9B0Q33406802-9BE40691-F32C-4131-9192-61461E411AD9Q33415594-86EF4E10-B3A4-45ED-8E80-DD67EC8463D3Q33418329-A5635A81-AE25-487C-A288-0E6065856D4CQ33429980-6D471213-B9C2-420E-BC1B-AA743E8402D5Q33434352-F194DA43-684B-4C04-854D-1A8CB6EA8C84Q33490630-04670ED2-3931-4649-8350-0C4AFE06A1C2Q33498538-7D53922E-44CE-4487-8363-6328D1656830Q33597441-8C6060E4-0C1D-4029-8F2C-25E0A9B9336EQ33626194-E08A7F84-8231-4A27-A685-CC3F1D7E8A31Q33714010-A580B83C-8A3E-4F91-9D93-E25EF43BEA5BQ33714464-2C321597-A2C2-42AC-8949-4AE3EDAF0668Q33730750-677FB863-AF8D-4462-9F08-EA65363D96FDQ33772533-2DDBC82D-E483-49F9-B289-D4CA678F8685Q33852864-7BA83C95-BECF-4EFB-AF05-2E93BA8A4BE8Q33918113-175CB315-2078-48BD-A103-0EFA8EA5CA81Q33932032-8AC1242C-2C8C-4CEB-B068-C24D56E7D31BQ33945668-DD11012E-8463-4212-9BDD-DE2842E2B09DQ34060237-55A54BAB-3B2C-4BB5-88CA-2098FEA6FE4A
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Design and analysis of phase I clinical trials.
@en
Design and analysis of phase I clinical trials.
@nl
type
label
Design and analysis of phase I clinical trials.
@en
Design and analysis of phase I clinical trials.
@nl
prefLabel
Design and analysis of phase I clinical trials.
@en
Design and analysis of phase I clinical trials.
@nl
P356
P1433
P1476
Design and analysis of phase I clinical trials.
@en
P2093
P304
P356
10.2307/2531693
P407
P577
1989-09-01T00:00:00Z